Journal of Molecular Medicine

, Volume 84, Issue 12, pp 997–1003

Thioredoxin in the cardiovascular system

  • Cameron J. World
  • Hideyuki Yamawaki
  • Bradford C. Berk
Review

DOI: 10.1007/s00109-006-0109-6

Cite this article as:
World, C.J., Yamawaki, H. & Berk, B.C. J Mol Med (2006) 84: 997. doi:10.1007/s00109-006-0109-6

Abstract

The thioredoxin (TRX) system (TRX, TRX reductase, and NADPH) is a ubiquitous thiol oxidoreductase system that regulates cellular reduction/oxidation (redox) status. The impairment of cell redox state alters multiple cell pathways, which may contribute to the pathogenesis of cardiovascular disorders including hypertension, atherosclerosis, and heart failure. In this manuscript, we review the essential roles that TRX plays by limiting oxidative stress directly via antioxidant effects and indirectly by protein–protein interactions with key signaling molecules such as thioredoxin interacting protein (TXNIP). TRX and its endogenous regulators may represent important future targets to develop clinical therapies for diseases associated with oxidative stress.

Keywords

AntioxidantsCardiovascular diseasesEndotheliumSmooth muscleSignal transduction

Abbreviations

ASK1

Apoptosis signal-regulating kinase 1

EC

Endothelial cell

JNK

Jun N-terminal kinase

PDGF

Platelet-derived growth factor

ROS

Reactive oxygen species

TRX

Thioredoxin

TXNIP

TRX-interacting protein

VCAM

Vascular cell adhesion molecule

VSMC

Vascular smooth muscle cell

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Cameron J. World
    • 1
  • Hideyuki Yamawaki
    • 2
  • Bradford C. Berk
    • 1
  1. 1.Cardiovascular Research Institute, Department of MedicineUniversity of RochesterRochesterUSA
  2. 2.Department of Epidemiology, Research InstituteNational Cardiovascular CenterOsakaJapan